Selecting the Right CRO for a Phase 2 Cell Therapy Hematology Study

Seuss+ helped a privately owned cell therapy biotech select the right CRO for a Phase 2 hematology study while protecting study timelines, budget, and data quality. By managing the evaluation from initial alignment through RFP, bid defense, and contract negotiations, we helped the sponsor reach an aligned decision, accelerate contracting by 1.5 months, and recover €2 million during contract review and negotiation.

Summary

A privately owned biotechnology company specializing in cell therapy was preparing for a Phase 2 study in hematological cancers.

The sponsor needed to select a CRO with the right capabilities for the study, but first its internal team needed to align on what the right partner should look like and how potential CROs would be assessed.

The selection process also needed to protect study timelines, budget, and data quality, while reducing the burden on the sponsor’s internal team.

We co-ordinated the process from initial alignment through RFP, bid defense, and contract negotiations. This gave the sponsor clear selection criteria, a documented evaluation process, and a consistent way to compare potential CRO partners.

Our support continued into contracting, where we accelerated negotiations by 1.5 months against the agreed timeline and recovered €2 million into the sponsor’s budget during contract review and negotiation.

The final agreement also strengthened CRO accountability and gave the sponsor greater protection against mistakes that could affect study delivery.

Clinical Trial Success in CNS
1.5
months saved in contract negotiations
€2m
recovered into the sponsor's budget
4
stages from alignment to contracting

What Seuss+ Delivered

CRO Selection and Contract Negotiation Built Around the Study.

We began by working with the sponsor team to define what it needed from its CRO partner. This included aligning on the selection criteria and identifying the requirements that mattered most when evaluating potential providers.

We then managed the RFP process, giving the sponsor a structured way to compare CRO capabilities against the agreed criteria.

The strongest candidates moved into bid defense, where we co-ordinated the evaluation and supported the sponsor in reaching a decision that worked across the organization, from functional teams through to the board.

Once the CRO had been selected, we moved into contract review and negotiation. Our work accelerated this stage by 1.5 months against the agreed timeline and recovered €2 million into the sponsor’s budget.

We also supported the negotiation of a sponsor-friendly MSA designed to strengthen CRO accountability, protect the sponsor from the impact of CRO errors, and set clearer expectations for performance throughout the study.

The Risk/Challenge

M

The sponsor needed to select the right CRO for a Phase 2 cell therapy hematology study

M

The internal team needed to align on the criteria that would define the right CRO partner

M

The CRO evaluation needed to be fully documented and inspection-ready

M

Study timelines needed to be protected throughout the selection and contracting process

M

Budget and data quality needed to remain central to the decision

M

The selection process needed to reduce the burden on the sponsor's internal team

M

Functional teams and the board needed confidence in the final CRO decision

M

The sponsor needed contract terms that created clear CRO accountability and protected against avoidable errors

The Results

N

Contract negotiations were completed 1.5 months faster than the agreed timeline

N

€2 million was recovered into the sponsor's budget during contract review and negotiation

N

The sponsor completed a fully documented CRO evaluation process

N

Teams across the organization aligned around the final CRO selection

N

The board had confidence in the decision and the process used to reach it

N

The sponsor secured an MSA designed to strengthen CRO accountability and performance

N

Contract terms gave the sponsor greater protection against mistakes made by the CRO

N

The selection and contracting process supported the sponsor's focus on study timelines, budget, and data quality

How We Helped

Aligned the sponsor team on CRO requirements and selection criteria

Defined the criteria used to assess potential CRO partners

Co-ordinated the CRO evaluation process from initial alignment through contracting

Designed and managed the RFP process

Assessed CRO responses against the agreed study requirements

Co-ordinated the bid defense process

Supported alignment across functional teams and the board

Managed CRO communications throughout the evaluation

Documented the selection process to create a clear audit trail

Managed contract review and negotiations

Accelerated contract negotiations by 1.5 months against the agreed timeline

Recovered €2 million into the sponsor's budget during contract review and negotiation

Negotiated an MSA designed to strengthen CRO accountability and performance

Reduced the operational burden on the sponsor's internal team throughout the process

Frequently Asked Questions

A CRO can only be assessed properly when the sponsor is clear about what the study needs and what matters most in the partnership. Aligning the team early creates consistent selection criteria and reduces the risk of different functions assessing potential CROs against different expectations.

Yes. Contract review is also an opportunity to examine responsibilities, assumptions, payment terms, accountability, and how risk is shared between sponsor and CRO. In this case, contract review and negotiation recovered €2 million into the sponsor's budget while also strengthening the terms governing CRO performance.

We can manage the structure, co-ordination, communications, evaluation, and documentation behind the selection process. This allows the sponsor's internal experts to focus their time where their input matters most, while still maintaining visibility and control over the final decision.

Schedule a consultation now

 

Key Takeaways

  • A privately owned cell therapy biotech preparing a Phase 2 study in hematological cancers needed its internal team aligned on what the right CRO looked like before any evaluation began.
  • Seuss+ ran the process from initial alignment through RFP, bid defense, and contract negotiations, reducing the load on the sponsor's internal team throughout.
  • Contract negotiations were completed 1.5 months faster than the agreed timeline.
  • Contract review and negotiation recovered €2 million into the sponsor's budget.
  • The sponsor secured an MSA that strengthens CRO accountability and protects against the impact of CRO errors, backed by a fully documented, inspection-ready evaluation.

The headline price is only the start of a CRO contract. The real value sits in the assumptions, the responsibilities, and who carries the risk when something goes wrong, and that is where this sponsor recovered €2 million.

Kieran Engels, CEO and Co-Founder of Seuss+

Negotiating a CRO contract?

Book a 30-minute call. We will walk through where the value sits in your CRO contract beyond the headline price.

Book an intro call